Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Marcin Kowanetz et al.|Nature Medicine|2018Cited by 1.2k
Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast CancersErica Schleifman, Mark R. Lackner|PLoS ONE|2014Cited by 36